Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,232 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,676 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02646839 | KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children | enrolling by invitation | Phase 2 | 50 | Michael PulsipherOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT04836390 | Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions in Children and Young Adults With High Risk Acute Myeloid Leukemia Receiving Myeloablative HLA-Haploidentical Hematopoietic Cell Transplant(EXCEL) | enrolling by invitation | Phase 2 | 30 | Michael PulsipherOTHER | 1 |
| May 4, 2025 |
| clinicaltrials |
| NCT06931613 | Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment | enrolling by invitation | Phase 2 | 20 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Apr 17, 2025 | clinicaltrials |
| NCT06925685 | Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product | enrolling by invitation | — | 50 | Allogene TherapeuticsINDUSTRY | 1 | Apr 13, 2025 | clinicaltrials |
| NCT03507842 | A Prospective Randomized Comparison of HDAC Vs AD in the Induction Chemothrapy for AML. | enrolling by invitation | Phase 3 | 380 | Asan Medical CenterOTHER | 1 | Mar 17, 2025 | clinicaltrials |
| NCT06560879 | Effectiveness of Probiotics for the Prevention of Gastrointestinal Toxicity in Children With Leukemia | enrolling by invitation | Phase 2 | 120 | National Institute of Pediatrics, MexicoOTHER_GOV | 1 | Mar 14, 2025 | clinicaltrials |
| NCT06871007 | Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma | enrolling by invitation | Phase 1 / Phase 2 | 22 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT06848738 | Improving Genomic Profiling and Reducing Time to Cancer Treatment Via Targeted Use of Endoscopic Ultrasound(IMPROVED) | enrolling by invitation | N/A | 362 | Zealand University HospitalOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT05674539 | Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome | enrolling by invitation | Phase 3 | 200 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT05212103 | PET Imaging of Cancer Patients Using 68Ga-DOTA-Siglec-9(CANSI) | enrolling by invitation | — | 30 | Turku University HospitalOTHER_GOV | 1 | Dec 4, 2024 | clinicaltrials |
| NCT06711679 | Exploring the Minimum Effective Concentration and Volume of Ropivacaine for Sacral Plexus Anesthesia | enrolling by invitation | Phase 4 | 180 | Yilin ZhaoOTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT05509855 | A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007 | enrolling by invitation | — | 44 | Allotera TherapeuticsINDUSTRY | 2 | Nov 20, 2024 | clinicaltrials |
| NCT06583395 | Quest to Analyze One Thousand Humans Meditating(QUANTUM) | enrolling by invitation | — | 3,000 | Tobias Moeller-BertramINDUSTRY | 1 | Nov 1, 2024 | clinicaltrials |
| NCT06664970 | A Multicenter Study on the Treatment of MDS/MPN Overlap Syndrome With AZA or Rux Combined With Selinexor | enrolling by invitation | Phase 2 | 39 | Peking Union Medical College HospitalOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT06646978 | Long-term Risk of Second Primary Malignancies for Chronic Myeloid Leukaemia in the French Imatinib-based SPIRIT Trial(K2SPIRIT) | enrolling by invitation | — | 787 | Poitiers University HospitalOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT06544109 | Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients(Ven APL) | enrolling by invitation | Phase 2 / Phase 3 | 98 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT05775224 | ASH Research Collaborative Data Hub | enrolling by invitation | — | 100,000 | ASH Research CollaborativeOTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT04210791 | Autologous Stem Cell Transplantation for Patients With AL Amyloidosis | enrolling by invitation | — | 500 | Nanjing University School of MedicineOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT05038722 | Function of Platelets Used for Transfusions | enrolling by invitation | — | 240 | Sofia RamströmOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT05889806 | AUD Biomarkers Study (Proteomic and Genomic Analysis of Biospecimens) | enrolling by invitation | — | 10,000 | Audubon BioscienceINDUSTRY | 1 | Jun 5, 2023 | clinicaltrials |
| NCT04491721 | Follow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera, in Untreated Subjects With CD20+ DLBCL | enrolling by invitation | — | 407 | Chinese Academy of Medical SciencesOTHER | 1 | Jul 29, 2020 | clinicaltrials |
| NCT03815279 | A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)(iStopMM) | enrolling by invitation | Phase 2 | 80 | Landspitali University HospitalOTHER | 1 | Aug 16, 2019 | clinicaltrials |
Data updated 22 days agoSource updated May 4, 2025source: clinicaltrials